abstract |
The present disclosure is a method of treating a patient with a CYP3A4 substrate drug contraindicated for co-administration with potent CYP3A4 inhibitors, wherein the patient is treated with multiple doses of posaconazole, after stopping the posaconazole treatment, and then CYP3A4 It provides a method that is treated with a substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 days after stopping posaconazole. In some embodiments, the patient is treated with or is prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 days after discontinuing posaconazole. |